View Older Stories View More Recent Stories
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK430 at Kepler Cheuvreux
-
This EU pharma stock offers 'unmatched' re-rating potential: analyst
-
EMA committee backs higher dose Wegovy for greater weight loss
-
Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics
-
Argus Downgrades Novo Nordisk (NVO) to Hold
-
Novo Nordisk (NVO) preparing to launch Ozempic in India in December - Reuters
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Novo Nordisk submits application for higher dose semaglutide
-
Bernstein on IRA pricing: $245 really is the floor
-
Novo Nordisk reports positive phase 2 results for diabetes drug amycretin
-
Novo Nordisk (NVO) call put ratio 1.6 calls to 1 put amid wide price movement
-
Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital
-
HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
-
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Novo Nordisk shares sink after Alzheimer’s drug trial failure
-
Novo Nordisk semaglutide fails to slow Alzheimer's disease in phase 3 trials
-
Septerna's (SEPN) Novo Pursuing a Multi-Billion-Dollar Opportunity- Cantor Fitzgerald
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
BMO Capital: 'Extraordinary General Meeting Sets the Stage for Novo Nordisk (NVO) Transformation'
-
Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
-
Mikael Dolsten withdraws board candidacy at Novo Nordisk
-
Mangoceuticals clarifies GLP-1 weight-management program launch
-
Lilly and Novo Nordisk say no affiliation with Mangoceuticals (MGRX)
-
Novo Nordisk cuts Wegovy price by as much as 33% in India - Reuters
-
Novo Nordisk shows semaglutide benefits in liver disease with minimal weight loss
-
Novo Nordisk's CagriSema shows blood pressure reduction in obesity trial
-
Novo CEO Says Bid For Metsera Is Higher Than Pfizer's Is Today
-
Novo Nordisk Is Said To Sweeten Bid For Obesity Startup Metsera - Bloomberg
-
Trump administration reaches GLP-1 drug pricing deals with Eli Lilly and Novo Nordisk - White House
-
Novo Nordisk commits additional $10B to U.S. investment - White House
-
Novo Nordisk (NVO) call put ratio 2.8 calls to 1 put with a focus on December 35 puts
-
Novo Nordisk (NVO) call put ratio 2 calls to 1 put amid price movement
-
Pfizer vows to continue Metsera legal fight after court denies restraining order
-
Novo Nordisk (NVO) PT Lowered to $50 at BMO Capital
-
Pfizer Preps Improved Offer In Metsera Bidding War - WSJ
-
Pfizer Denied Temporary Block On Novo Nordisk’s Metsera Bid - Bloomberg
-
Pfizer Drops Demand That Metsera Denounce Novo Bid: Metsera - Bloomberg
-
FTC Says Novo-Metsera Bid Raises Merger Filing Concerns - Bloomberg
-
Pfizer has removed conditions on sale of Arch Venture shares and Metsera public statements from its Metsera bid - Pfizer letter to court
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Novo Nordisk (NVO) Reports Q3 EPS of DKK4.50; offers outlook
-
Novo Nordisk earnings preview: Barclays and BofA weigh in
-
Trump admin talking to Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumpRx - WSJ
-
Novo Nordisk (NVO) call put ratio 3.1 calls to 1 put into quarter results
-
Pfizer (PFE) CEO: our bid for Metsera has taken into consideration that prices of GLP-1 will probably start going down - Conference Call
-
Lilly and Novo near White House deal on obesity drug prices - Endpoints News
-
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies - FT
-
Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
